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Colon cancer is a serious health problem, and novel preventive and therapeutical avenues are urgently called for. Delivery of
proteins with anticancer activity through genetically modiﬁed bacteria provides an interesting, potentially speciﬁc, economic and
eﬀective approach here. Interestingly, bone morphogenetic protein 2 (BMP-2) is an important and powerful tumour suppressor
in the colon and is thus an attractive candidate protein for delivery through genetically modiﬁed bacteria. It has not been shown,
however, that BMP production in the bacterial context is eﬀective on colon cancer cells. Here we demonstrate that transforming
E. coli with a cDNA encoding an ileal-derived mature human BMP-2 induces eﬀective apoptosis in an in vitro model system for
colorectal cancer, whereas the maternal organism was not eﬀective in this respect. Furthermore, these eﬀects were sensitive to
cotreatment with the BMP inhibitor Noggin. We propose that prevention and treatment of colorectal cancer using transgenic
bacteria is feasible.
1.Introduction
Bonemorphogenetic protein(BMP)isamemberofthelarge
TGF-β superfamily of morphogenetic ligands. Originally
BMP was identiﬁed as a morphogen involved in bone
formation, and later this protein emerged as an important
signalling mediator during embryonic development and as a
critical component of the morphogenetic code in derivatives
of all three germ layers [1]. BMP signalling is antagonized
by endogenous extracellular proteins, such as noggin, which
bind BMPs and thus limit the extent of BMP signalling [2].
BMP binds to Type I (BMPR1A, BMPR1B) and Type II
(BMPRII) serine-threonine kinase transmembrane receptors
andtriggersasignaltransductioncascadesmediatedthrough
the Smad cascade of signal transducers. Signalling through
Smads takes place via three diﬀerent classes of Smad family
proteins: receptor-regulated Smads (Smad1, 5, and 8), co-
Smad/Smad 4 (common mediator of Smad), and inhibitory
Smads (Smad 6 and 7, negative regulators of Smad). Finally
the BMP-Smad pathway activates direct or indirectly BMP
target genes in the nucleus via cotranscriptional partners
(Figure 1)[3].Thus,BMPformsacomplexwithextracellular
matrix proteins; for this reason its biological activity is con-
ﬁned to a local niche, tribute to its powerful morphogenetic
action.
BMP-2 has a crucial role during the embryonic devel-
opment of digestive organs, for instance in stomach gland
formation [4]. Expression is maintained through adulthood
where it helps maintaining tissue homeostasis in this con-
tinuously regenerating organ [5], and its presence seems
required to suppress transformation in vivo, for instance,
following Helicobacter infection [6] or at the cancer-prone
transition zones [7]. Likewise, also the colon is characterized
by high expression of BMP-2 [6, 8, 9], where genetic loss
of signalling components is intimately associated with the
development of both sporadic cancer [10, 11]a n dw i t h
genetic polyposis syndromes, in particular juvenile polyposis
[12] and also in gastric and colorectal cancer methylation2 Gastroenterology Research and Practice
Smad 1,5 & 8
P
h
o
s
p
h
o
r
y
l
a
t
e
s
 
BMPR2 1
Nucleus 
Smad 6 & 7
Cell membrane
BMP-2 ligands
BMP-2-noggin complex
Phosphorylates
and activates
Smad 4
Smad 4
Smad 4
Smad 4
Smad 1, 5 & 8
Complex with
Binds
Translocate
BMPR1
Figure 1: BMP binds to Type I (BMPR1A, BMPR1B) and Type II (BMPRII) serine threonine kinase transmembrane receptors and triggers
a signal transduction cascade initiated via Smad family proteins. Signaling cascade through Smad take place via three Smad family proteins:
receptor-mediated Smads.
of the BMP-2 promoter is a frequent event [13]. Especially
important is also that the preventive action of statins on the
development of colorectal cancer is mediated through the
BMP pathway [14], producing epigenetic reprogramming
and reducing colorectal cancer cell stemness [15, 16]. In
apparent agreement, also in other parts of gastrointestinal
tract, BMP signaling is intimately linked to the cancer
process. BMP-2 is a negative regulator of hepatocyte pro-
liferation downregulated in the regenerating liver [17],
although in the oesophagus BMP-2 production may actually
be implicated in induction of the precancerous condition
Barrett’s esophagus [18]. Together, these data indicate that
BMP-2 acts as a powerful tumor suppressor in the columnar
intestine and thus that application of exogenous BMP-2 may
be useful in combating cancer cells. In agreement with such
an application of BMP-2, Wen et al. have demonstrated that
BMP-2 inhibited cell growth and induced cell diﬀerentiation
in normal and cancerous gastric cell lines [19].
Colon cancer is an epithelial cancer which develops as
a result of uncontrolled cellular proliferation and dysregu-
lation of cellular apoptotic mechanisms [20], and its patho-
genesis is undoubtedly related to the complex interaction
of mucosal immunology with the microbiological ecology
[21]. Conventional treatment for colon cancer such as
surgery, radiotherapy, and chemotherapy has only limited
eﬃcacy and leads to serious side eﬀects. Likewise cur-
rent chemopreventive strategies only partially reduce risk,
whereas endoscopic screening is expensive and unpopular
with patients. Targeted therapies that by local application
of anticancer molecules induce apoptosis in early phases of
cancer development would evidently represent an important
step forward. In this sense oral ingestion of genetically
engineered bacteria may represent a golden bullet, as they
by deﬁnition limit their action to the mucosa and are
c h e a pt op r o d u c ea n da p p l yt op a t i e n t s[ 22, 23]. The power
of this strategy has been demonstrated in a variety of
preclinical models [24–27] directed at combating mucosal
inﬂammation using the production of immunomodulatory
molecules, and the applicability of such a strategy for
human disease was convincingly shown in a clinical trial of
Lactococcus lactis producing interleukin-10 to treat Crohn’s
disease [28]. The applicability for preventing or treating
early cancer has not been investigated, however. Evidently,
however, mucosal delivery of the colonic tumour suppressor
BMP-2 could prove highly interesting in this respect, but
would require proof that BMP produced in the bacterial
context is capable of counteracting colon cancer cells. BMP-
2 has been produced from mammalian cell cultures and
in plants as active form [29]. Demonstration of eﬃcacy
on colon cancer cells of bacterially produced BMP-2 would
constitute an important step forward to come to applying
transgenic bacteria for cancer prevention. Here we show that
BMP-2 can be successfully expressed by E. coli and that such
bacteria can kill cancer cells in a noggin-sensitive fashion,
providing proof of principle for this strategy.
2.Methods andMaterials
2.1. DLD-1 Culture. DLD cells were cultured at 37◦Cu n d e r
a humidiﬁed 95% O2/5% CO2 atmosphere. The attaching
DLD cells were cultured in RPMI supplemented with 10%
fetal calf serum according to routine procedures.
2.2. Cloning of Human BMP-2. The human BMP-2 cDNA
sequence was ampliﬁed by PCR using the primer 5 ATT-
GCCGGCGACCCGCTGTCTTCTA 3a n d5  ATCGATGCG-
ACACCCACAAC 3 from normal human ileum. The primers
contained the ClaI and NgoMIV restriction sites for futureGastroenterology Research and Practice 3
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Figure 2: Schematic layout of the pTrcHis TOPO TA expression
vector (Invitrogen, Netherland) used in this study for prokaryotic
expression and the strategy employed to insert the ileal-derived
human BMP-2 in this vector. The same vector, but driving LacZ
expression, was used as control organism.
cloning into L. lactis. The entire PCR product was cloned
into the Topo pTris prokaryotic expression vector and
transformed into E. coli K-12 strain (Figure 2). The new
plasmid was named as pTrisBMP-2. Conﬁrmation of cloning
and transformation was done by PCR on E. coli colonies
using above-mentioned primer to conﬁrm the presence of
human BMP-2 in the colonies. Next, restriction enzyme
analysis was performed, using BamHI and AgeI, to conﬁrm
correct orientation of the insert (human BMP-2) into the
pTrcHis TOPO TA expression vector. The expected size of a
correct orientation of the insert in the backbone was 291bp,
and with a reversed orientation 1030bp. Subsequently the
positive colonies were sequenced and checked for correct
reading frame.
2.3. Expression of BMP-2 in E. coli. The E. coli strain K-12
transformed with pTrisBMP-2 was cultured in LB medium
containing ampicillin (50μg/mL) at 37◦C; when the OD600
of culture reached 0.6, the expression of BMP-2 was induced
by addition of IPTG to a ﬁnal concentration of 1mM and
cultivated for 2 more hours [30].
2.4. Western Blotting. Expression of BMP-2 was conﬁrmed
by the western blotting [31]. The molecular weight of the
protein was checked by SDS-PAGE, which present 44kDa.
Forimmunodetection,sampleswereseparatedbySDS-PAGE
and electrotransferred to a nitrocellulose membrane. The
membranewasblockedwith5%nonfatmilkinPBS-Tbuﬀer
(PBS containing 0.05% Tween 20) and then incubated with
mouse anti-human BMP-2 polyclonal antibody (1:2000)
and Rabbit anti-His tag (1:5000) antibodies for 2 hours.
The membrane was washed three times with PBS-T buﬀer
and then incubated in anti-mouse and anti-rabbit HRP-
conjugated secondary antibody at 1:2000 dilution in PBS-
Tb u ﬀer for 1 hour. The membrane was washed three
times with PBS-T buﬀer, and the expressed proteins were
visualized using ECL plus western blotting detection system
(Amersham).
2.5. Coculture of DLD Cells and E. coli and Caspase Activity
Assay. Experiments to address the eﬀects of BMP-2 pro-
ducedfromtheprokaryoticexpressionvectoronapoptosisof
cancer cells were performed as follows: an overnight culture
of BMP-2 containing E. coli was inoculated in LB-broth until
the OD600 reached 0.6 and induced with 1mM IPTG. The
induced bacteria were incubated with a conﬂuent DLD-1
cell culture (with 10% FCS) in 6-well plates for 5 hours.
The cells were lysed, and the protein concentrations were
estimated using BIO-Rad DC Protein Assay kit (Bio-Rad).
Caspase-3 activity was assayed in cells using a ﬂuorimetric
kit (Promega) according to the manufacturer’s instructions.
Brieﬂy, the proluminescent substrate containing the DEVD
(sequences are in a single-letter amino acid code) is cleaved
by caspase-3. After caspase cleavage, a substrate for luciferase
(aminoluciferin) is released; this results in the luciferase
reaction and the production of luminescent signal. An equal
volume of reagents and 20μg/mL proteins from the treated
DLD-1 cells were added to a white-walled 96-well plate and
incubated at room temperature for 1h. The luminescence of
each sample was measured in a plate-reading luminometer
[32–35].
3. Results
3.1. Construction of pTrisBMP-2. Although prevention of co-
lorectal cancer through the delivery of tumour suppressive
cytokines to cancer cells by transgenetic bacteria is an
attractive approach, it has not yet been shown that such
cytokines can inﬂuence cancer cells when produced in bac-
terial context. To address this conceptual issue, the human
BMP-2 gene was ampliﬁed from cDNA derived from normal
ileum by PCR. The 1088bp product was successfully cloned
into pTris as to obtain the pTrisBMP-2 vector, and using
PCR and restriction analysis the plasmid which contained
the BMP-2 gene in the correct orientation was selected.
Subsequent sequence analysis revealed that the obtained
BMP-2 was in the right reading frame with three mutations
were observed where one led to a change in the amino acid.
T h i sm u t a t i o nm a yb ed u et oaT a qe r r o ro rt oa na c q u i r e d
mutation in the volunteer from which the BMP-2 gene was
derived. The vector obtained lends it well for prokaryotic
transformation,andsubsequentlyexperimentswereinitiated
to which extent it also allows production of BMP through
bacteria.
3.2. BMP-2 Expression in E. coli. Small-size cultures (10mL)
of the positive clones of pTrisBMP-2 were subjected to4 Gastroenterology Research and Practice
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Figure 3: Illustration of expression of the transgene. Western blot
analysis of BMP-2 expression in transformed E. coli. Panel A shows
analysis of employing a poly-His tag antibody after 1hr of IPTG
induction (labelled 1) and after 3hrs of IPTG induction (labelled
2). Panel B shows analysis of employing an anti-BMP-2 antibody
after 1hr of IPTG induction (labelled 1) and after 3hrs of IPTG
induction (labelled 2).
IPTG induction to identify clones capable of expressing
high levels of the recombinant protein. Ten clones showed
expression of the unique predicted 44kDa protein after
IPTGinduction.TheBMP-2productionincreasedinparallel
with the duration of induction. Without IPTG induction,
two clones did not show the expression of this protein as
conﬁrmed by SDS-PAGE. The expression of the BMP-2 was
further conﬁrmed by western blot using anti-BMP-2 and
anti-His tag antibody (Figure 3). We concluded that we can
eﬃciently express BMP-2 through a bacterial vector and
that the resulting bacterial clones would allow testing of
whether production of the tumour suppressive cytokine in
this bacterial context has anticancer activity.
3.3. Apoptosis Assay. E. coli colonies were cocultured with
DLD-1 cells for diﬀerent time periods, and afterwards the
potential and colon cancer activity of the bacterial on the
cancer cells were assessed using caspase-3 activity as pseudo-
endpoint. Importantly, control bacteria which express the
LacZ gene (which we assume to be inert) do not provoke
marked apoptosis in colorectal cancer cultures; thus bacteria
per se do not seem to exert signiﬁcant activity in this respect.
Colon cancer cultures, however, co-cultured with bacteria
containing the BMP-2 gene exhibited signiﬁcant caspase-3
activity, testimony of a potent anticancer activity (Figure 4).
Althoughcaspase-3isarelativelylatemarkerintheapoptotic
process, evident activation of the cysteine protease was
clearly visible already after 5hrs of coculture. The speciﬁcity
of the eﬀect is demonstrated by its sensitivity to the speciﬁc
BMP antagonist noggin (data not shown). We conclude
that tumour-suppressive cytokines can be produced through
prokaryotes and retain eﬃcacy in the bacterialcontext. Thus,
we propose that mucosal delivery of tumour-suppressive
cytokines is feasible.
4. Discussion
The clinical trail utilising IL-10 expressing L. lactis for the
treatment of Crohn’s disease has conﬁrmed that such bac-
teria represent a viable approach for the mucosal release
of therapeutically exciting proteins. This has opened new
avenues to explore and use transgenic bacteria as a vehicle
for delivery of this type of target molecules locally and
as a consequence avoid the unwanted side eﬀects which
occur when such therapeutics are administered systemically.
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Figure 4: Illustration of expression anticancer activity of trans-
formed bacteria on colon cancer cultures. BMP-2 expressing
colonies were co-cultured with DLD-1 cells. Caspase-3 activity was
measured using a ﬂuorescent detection methodology. Colonies 4
and 5 show a signiﬁcant higher caspase-3 activity compared to
the negative control. Statistical signiﬁcance was conﬁrmed using a
heteroscedastic two-sided Student’st-test.In thisﬁgure thenegative
control was bacteria containing a LacZ gene.
Whether this approach was also feasible for the delivery of
tumour-suppressive cytokines remained unclear. Especially
the capacity of prokaryotic organisms to produce function-
ally relevant amounts of such molecules and whether these
molecules would retain eﬃcacy when delivered to cancer
cells in the bacterial context remained unexplored. Here
we show large amounts of BMP-2 expressed by E. coli.
Furthermore, we report a potential approach for inducing
colon cancer cells death by apoptosis mediated by the
recombinant BMP-2 protein produced by this E. coli.I n
recent years, a better perceptive of pathogenic mechanisms
has provided novel targets and strategies for colon cancer
therapy. These vary from novel chemotherapeutic agents,
therapeutic antibodies, to target small molecules involved in
the signal transduction. The successful clinical trails to treat
patients with IBD using L. lactis producing IL-10 now opens
the window to deliver anticancer agent via oral therapy with
recombinant bacteria. Thus transgenic bacteria may become
a vehicle to deliver associated target molecules locally and
consequently avoid unwanted side eﬀects associated with
systemic administration.
BMP-2 expressed in E. coli shows clear proapoptotic
eﬀects when cocultured with DLD-1 cells. Although E. coli
does not have the same posttranslation modiﬁcation system
as that present in humans, the normal vector for intestinal
BMP-2 production, the BMP-2 produced by this bacterium,
is evidently biologically active, and thus diﬀerences in
prokaryotic and eukaryotic protein processing can be over-
come. Recently many signalling pathway mediators involved
incancerhavebeenidentiﬁedwhicharepromisingtargetsfor
cancer therapy. These molecules should be delivered specif-
ically to the cancer cells by targeting to tumour cells. Based
on these requirements, we developed a recombinant human
BMP-2molecule.AdditionofnogginwhichisantagonistictoGastroenterology Research and Practice 5
BMP-2 inhibited apoptosis, further illustrating speciﬁcity. In
total, our experiments provide proof of concept that mucosal
delivery of therapeutic proteins is feasible, and the promising
results obtained further encourage to continue by expressing
the recombinant BMP-2 on the surface of L. lactis which
would represent a next step in quest to combat colon cancer
through transgenic bacteria.
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